Payment overview · 2025
General Payments
$1,000.16
63 reported records · 16 companies
Healthcare provider profile · identity verified
Beata Styka, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Geriatric Medicine · PALOS HEIGHTS, IL · NPI 1275623233
Verified facts
What the public records show
CMS Open Payments records show Beata Styka, M.D. received $1,000.16 in general payments during 2025 across 63 reported records.
PFIZER INC. accounted for 29.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Ozempic, Paxlovid, Synthroid, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 300 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 136 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 300 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $294.21 | 29.4% | 26 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $180.05 | 18.0% | 10 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $116.04 | 11.6% | 7 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $66.45 | 6.6% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $60.35 | 6.0% | 3 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $45.72 | 4.6% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $36.24 | 3.6% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $35.38 | 3.5% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $26.52 | 2.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.76 | 2.5% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $23.06 | 2.3% | 1 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $20.42 | 2.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $19.94 | 2.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.87 | 1.8% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $17.57 | 1.8% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $15.58 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,000.16 | 63 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $190.62 | 15 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $183.99 | 14 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $146.44 | 8 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $146.44 | 8 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $96.24 | 6 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $85.91 | 10 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $60.35 | 3 | 2025 |
Source payment records
|
|||||
| VOWST Normalized: vowst |
Biological | Aimmune Therapeutics, Inc. | $45.72 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $44.00 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $36.24 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $33.61 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $26.52 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $20.98 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $20.98 | 1 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $20.42 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.94 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $19.94 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $19.80 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $17.87 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.87 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $17.57 | 1 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $17.03 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $15.84 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $15.84 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $15.84 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $15.58 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.40 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 300 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 136 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 32 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 93 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 98 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
93 | 24 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
300 | 67 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
98 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
136 | 26 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
300 | 67 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
32 | 32 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1067 | 285 |
| Amlodipine Besylate | Amlodipine Besylate | 1020 | 280 |
| Levothyroxine Sodium | Levothyroxine Sodium | 943 | 256 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 901 | 259 |
| Metoprolol Succinate | Metoprolol Succinate | 838 | 223 |
| Pantoprazole Sodium | Pantoprazole Sodium | 689 | 203 |
| Losartan Potassium | Losartan Potassium | 600 | 163 |
| Alprazolam | Alprazolam | 370 | 107 |
| Lisinopril | Lisinopril | 366 | 105 |
| Escitalopram Oxalate | Escitalopram Oxalate | 320 | 84 |
| Gabapentin | Gabapentin | 313 | 75 |
| Sertraline Hcl | Sertraline Hcl | 308 | 64 |
| Potassium Chloride | Potassium Chloride | 303 | 92 |
| Omeprazole | Omeprazole | 302 | 78 |
| Eliquis | Apixaban | 300 | 67 |
| Furosemide | Furosemide | 275 | 93 |
| Metoprolol Tartrate | Metoprolol Tartrate | 273 | 69 |
| Hydrochlorothiazide | Hydrochlorothiazide | 255 | 73 |
| Simvastatin | Simvastatin | 255 | 73 |
| Tramadol Hcl | Tramadol Hcl | 253 | 62 |
| Metformin Hcl | Metformin Hcl | 223 | 64 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 215 | 120 |
| Montelukast Sodium | Montelukast Sodium | 212 | 59 |
| Pravastatin Sodium | Pravastatin Sodium | 196 | 56 |
| Allopurinol | Allopurinol | 191 | 59 |
| Duloxetine Hcl | Duloxetine Hcl | 176 | 39 |
| Glimepiride | Glimepiride | 173 | 54 |
| Trazodone Hcl | Trazodone Hcl | 162 | 39 |
| Prednisone | Prednisone | 153 | 106 |
| Meloxicam | Meloxicam | 144 | 39 |
| Ezetimibe | Ezetimibe | 143 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 138 | 30 |
| Ozempic | Semaglutide | 136 | 26 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 132 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 131 | 31 |
| Cephalexin | Cephalexin | 130 | 98 |
| Memantine Hcl | Memantine Hcl | 121 | 22 |
| Donepezil Hcl | Donepezil Hcl | 115 | 23 |
| Metformin Hcl Er | Metformin Hcl | 113 | 34 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 110 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 105 | 34 |
| Torsemide | Torsemide | 102 | 30 |
| Citalopram Hbr | Citalopram Hydrobromide | 100 | 21 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 98 | 20 |
| Methylprednisolone | Methylprednisolone | 97 | 83 |
| Azithromycin | Azithromycin | 95 | 82 |
| Synthroid | Levothyroxine Sodium | 93 | 24 |
| Mirtazapine | Mirtazapine | 91 | 28 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 90 | 70 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 90 | 61 |
| Lorazepam | Lorazepam | 89 | 29 |
| Enalapril Maleate | Enalapril Maleate | 76 | 22 |
| Atenolol | Atenolol | 73 | 21 |
| Bupropion Xl | Bupropion Hcl | 73 | 16 |
| Baclofen | Baclofen | 72 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 71 | 33 |
| Famotidine | Famotidine | 69 | 23 |
| Carvedilol | Carvedilol | 68 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 68 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 68 | 12 |
| Lovastatin | Lovastatin | 66 | 20 |
| Clonazepam | Clonazepam | 64 | 13 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 57 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 56 | 13 |
| Januvia | Sitagliptin Phosphate | 52 | 14 |
| Alendronate Sodium | Alendronate Sodium | 50 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 50 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 49 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 47 | 11 |
| Nifedipine Er | Nifedipine | 47 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 47 | suppressed |
| Irbesartan | Irbesartan | 46 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 45 | 36 |
| Cefdinir | Cefdinir | 45 | 36 |
| Meclizine Hcl | Meclizine Hcl | 45 | 25 |
| Benazepril Hcl | Benazepril Hcl | 44 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 44 | 14 |
| Xarelto | Rivaroxaban | 44 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 43 | 14 |
| Ipratropium Bromide | Ipratropium Bromide | 42 | 22 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 39 | 12 |
| Finasteride | Finasteride | 39 | suppressed |
| Myrbetriq | Mirabegron | 39 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | suppressed |
| Ketoconazole | Ketoconazole | 38 | 29 |
| Fenofibrate | Fenofibrate Nanocrystallized | 37 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 37 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 35 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 35 | 11 |
| Mupirocin | Mupirocin | 35 | 27 |
| Nystatin | Nystatin | 35 | 18 |
| Pregabalin | Pregabalin | 35 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 34 | 11 |
| Ramipril | Ramipril | 34 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 32 | suppressed |
| Digoxin | Digoxin | 32 | suppressed |
| Klor-Con M20 | Potassium Chloride | 32 | 11 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 32 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 32 | 32 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 32 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 31 | suppressed |
| Telmisartan | Telmisartan | 31 | suppressed |
| Vascepa | Icosapent Ethyl | 31 | suppressed |
| Glipizide | Glipizide | 30 | suppressed |
| Levetiracetam | Levetiracetam | 30 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 30 | suppressed |
| Repaglinide | Repaglinide | 30 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 29 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 28 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 27 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 27 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 26 | suppressed |
| Colchicine | Colchicine | 26 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 19 |
| Sulfasalazine | Sulfasalazine | 26 | suppressed |
| Topiramate | Topiramate | 26 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 25 | suppressed |
| Chlorthalidone | Chlorthalidone | 24 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 22 |
| Nystop | Nystatin | 23 | 20 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Verapamil Er | Verapamil Hcl | 23 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 22 | suppressed |
| Calcitriol | Calcitriol | 22 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 21 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 21 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 20 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 17 | suppressed |
| Bumetanide | Bumetanide | 17 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | 12 |
| Valsartan | Valsartan | 17 | suppressed |
| Clotrimazole | Clotrimazole | 16 | 11 |
| Diazepam | Diazepam | 16 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 16 | 16 |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 15 | suppressed |
| Indapamide | Indapamide | 15 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 15 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 15 | suppressed |
| Trueplus Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 14 | suppressed |
| Folic Acid | Folic Acid | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Jardiance | Empagliflozin | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Verapamil Sr | Verapamil Hcl | 13 | suppressed |
| Xanax | Alprazolam | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Erythromycin | Erythromycin Base | 11 | suppressed |
| Glyburide | Glyburide | 11 | suppressed |
| Lyrica Cr | Pregabalin | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | 11 |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,000.16 · 63 records | PFIZER INC. | ABRYSVO, AIRSUPRA, AMYVID, BREZTRI, COMIRNATY, ELIQUIS, GEMTESA, KISUNLA, Korlym, Leqembi, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, PREVNAR 20, REPATHA, Rybelsus, SAPIEN 3 Ultra RESILIA, SYNTHROID, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VOWST, VRAYLAR, YUPELRI, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error